GLB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1899911	0.90	7/20
SCHEMBL3502620	0.90	7/20
SCHEMBL3501641	0.74	7/20
SCHEMBL1894661	0.74	5/20
SCHEMBL3502324	0.74	5/20
SCHEMBL1894899	1.00	4/20
SCHEMBL1894910	1.00	4/20
SCHEMBL1895630	1.00	4/20
SCHEMBL1895709	1.00	4/20
SCHEMBL3501077	1.00	4/20
SCHEMBL3501177	1.00	4/20
SCHEMBL3501774	1.00	4/20
SCHEMBL3502233	1.00	4/20
SCHEMBL1077400	0.65	4/20
SCHEMBL1034124	0.60	4/20
SCHEMBL1034127	0.60	4/20
SCHEMBL1034677	0.60	4/20
SCHEMBL1034680	0.60	4/20
SCHEMBL3663751	0.58	4/20
SCHEMBL1615494	0.55	4/20

Clinical trials — most relevant to GLB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease	PHASE3	COMPLETED
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms	PHASE3	COMPLETED
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease	PHASE3	COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease	PHASE2	WITHDRAWN
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia	PHASE1/PHASE2	NOT_YET_RECRUITING
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease	PHASE2	UNKNOWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Natural History of Morquio B and Late-Onset of GM1 Gangliosidosis	nan	UNKNOWN
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Assessment of Neurological Manifestations in Gaucher Disease Patients	nan	UNKNOWN
An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)	nan	WITHDRAWN
Effect of Migalastat on Cardiac Involvement in Fabry Disease	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Efficacy of a Probiotic Formulation in Adults With Lactose Intolerance and Methanogenic Intestinal Overgrowth	nan	COMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease	nan	COMPLETED
Biomarker for Patients With Fabry Disease (BioFabry)	nan	WITHDRAWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease	nan	COMPLETED
Evaluation of Phenotypic Variability in Fabry Disease	nan	WITHDRAWN
Alpha-galactosidase Enzyme and Irritable Bowel Syndrome	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GLB1 binder may also engage these)

Protein	Name	Similarity
Q5R7P4	—	1.000	Q5R7P4 →
Q60HF6	—	1.000	Q60HF6 →
Q58D55	—	1.000	Q58D55 →
P23780	—	1.000	P23780 →
Q6UWU2	—	1.000	Q6UWU2 →
Q95LV1	—	1.000	Q95LV1 →
O19015	—	1.000	O19015 →
Q8VC60	—	1.000	Q8VC60 →
Q9TRY9	—	1.000	Q9TRY9 →
Q0DGD7	—	1.000	Q0DGD7 →
Q8IW92	—	0.998	Q8IW92 →
Q93Z24	—	0.998	Q93Z24 →
A2RSQ1	—	0.997	A2RSQ1 →
P45582	—	0.997	P45582 →
Q8NCI6	—	0.997	Q8NCI6 →
Q5XIL5	—	0.996	Q5XIL5 →
Q9SCV9	—	0.996	Q9SCV9 →
Q7G3T8	—	0.995	Q7G3T8 →
Q67VU7	—	0.995	Q67VU7 →
Q00662	—	0.995	Q00662 →
Q8RUV9	—	0.995	Q8RUV9 →
Q10RB4	—	0.995	Q10RB4 →
Q3UPY5	—	0.994	Q3UPY5 →
P49676	—	0.994	P49676 →
Q0INM3	—	0.994	Q0INM3 →
Q6ZJJ0	—	0.993	Q6ZJJ0 →
P48980	—	0.993	P48980 →
B8N2I5	—	0.993	B8N2I5 →
Q9SCV3	—	0.993	Q9SCV3 →
C0HLA0	—	0.993	C0HLA0 →